Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Replagal and Fabrazyme reviews

Executive Summary

Genzyme's Fabrazyme (agalsidase beta) and TKT's Replagal (agalsidase alfa) will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13 and 14. The committee was originally slated to review the BLAs on Sept. 26-27. The delay apparently resulted from concerns raised by TKT about potential conflicts of interest among certain committee-invited guests (1"The Pink Sheet" Oct. 7, p. 23). The meeting will begin at 8 a.m. both days at the Holiday Inn in Bethesda, Md. [To view a 2webcast/video of each of these meetings, go to FDAAdvisoryCommittee.com]....
Advertisement

Related Content

Replagal Advisory Committee Meeting Possible By End Of The Year, TKT Says
Replagal Advisory Committee Meeting Possible By End Of The Year, TKT Says
Advertisement
UsernamePublicRestriction

Register

PS040742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel